Each month, Practical Guidance expands its library with tools, templates, and practice notes designed to help legal practitioners move faster and stay aligned with evolving legal requirements. The November...
By: Neil F. Aragones , Sean Craig , Susan C. Hughes , Peter C. Miller , Rosann Torres , and Charles R. Zubrzycki , Practical Guidance The following text is a summary of the full treatise section, available...
New ADAM Program Dashboard Aims to Increase Public Awareness of Missing Children An interactive dashboard launched recently by LexisNexis Risk Solutions is designed to increase public access to information...
By: Davis C. Bae , Sheldon J. Blumling , Ted Boehm , Benjamin M. Ebbink , David S. Jones , and Jennifer S. Kiesewetter , Fisher & Phillips LLP The following article is a summary of the full checklist...
By: The Practical Guidance Team The following article is a summary of the full practice note, available to Practical Guidance subscribers by following this link . Not yet a Practical Guidance subscriber...
Copyright © 2025 LexisNexis and/or its Licensors.
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
By: Matthew D. Jenkins, Hunton Andrews Kurth LLP
This article provides an overview of compliance obligations and federal False Claims Act (FCA) risks to healthcare and life sciences companies arising out of three funding streams made available in response to the COVID-19 pandemic: (1) Medicare’s Advance Payment Program, (2) the Provider Relief Fund, and (3) the Paycheck Protection Program.
When you advise a healthcare company that receives federal funds about its compliance obligations, a basic understanding of the FCA is essential.
The FCA imposes civil penalties on persons who knowingly or with reckless disregard: CLICK HERE TO READ THE FULL ARTICLE IF YOU ARE A PRACTICAL GUIDANCE SUBSCRIBER